UY33231A - Aminotiazolonas como moduladores de los receptores de estrógenos alfa - Google Patents

Aminotiazolonas como moduladores de los receptores de estrógenos alfa

Info

Publication number
UY33231A
UY33231A UY0001033231A UY33231A UY33231A UY 33231 A UY33231 A UY 33231A UY 0001033231 A UY0001033231 A UY 0001033231A UY 33231 A UY33231 A UY 33231A UY 33231 A UY33231 A UY 33231A
Authority
UY
Uruguay
Prior art keywords
modulators
estrogen
aminotiazolonas
alfa
receivers
Prior art date
Application number
UY0001033231A
Other languages
English (en)
Inventor
Bignan Gilles
Gaul Michael
Xu Guozhang
Bao-Ping Zhao
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of UY33231A publication Critical patent/UY33231A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se relaciona con nuevos compuestos de la Formula (I), métodos para preparar compuestos, composiciones, intermedios y derivados de estos para el tratamiento de condiciones tales como, el cáncer, la artritis, la enfermedad inflamatoria de las vías respiratorias y trastornos metabólicos. Más particularmente, los compuestos de la presente invención son moduladotes de los receptoras de estrógeno alfa (ERR-a alfa) útiles para el tratamiento, mejorar o inhibir la progresión de estados de enfermedad, trastornos y condiciones mediadas por la actividad ERR-a alfa.
UY0001033231A 2010-02-17 2011-02-17 Aminotiazolonas como moduladores de los receptores de estrógenos alfa UY33231A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30518110P 2010-02-17 2010-02-17

Publications (1)

Publication Number Publication Date
UY33231A true UY33231A (es) 2011-08-31

Family

ID=43927926

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001033231A UY33231A (es) 2010-02-17 2011-02-17 Aminotiazolonas como moduladores de los receptores de estrógenos alfa

Country Status (13)

Country Link
US (1) US8445690B2 (es)
EP (1) EP2536717B1 (es)
JP (1) JP2013519730A (es)
KR (1) KR20130001242A (es)
CN (1) CN102834392A (es)
AR (1) AR080207A1 (es)
AU (1) AU2011218190A1 (es)
CA (1) CA2789757A1 (es)
MX (1) MX2012009529A (es)
RU (1) RU2012139463A (es)
TW (1) TW201144303A (es)
UY (1) UY33231A (es)
WO (1) WO2011103134A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013051632A1 (ja) * 2011-10-04 2013-04-11 武田薬品工業株式会社 含窒素縮合複素環化合物
EP2832367B1 (en) 2012-03-26 2020-07-15 Nippon Chemiphar Co., Ltd. Agent for preventing or treating giant cell tumor or chondrosarcoma arising in bone/soft tissue
CN104119285B (zh) * 2013-04-28 2016-06-29 中国科学院广州生物医药与健康研究院 用作雌激素相关受体调节剂的化合物及其应用
KR20220000993A (ko) 2013-09-25 2022-01-04 닛뽕 케미파 가부시키가이샤 골·연부에 발생하는 거세포성 종양, 연골육종 또는 골육종의 예방, 치료 또는 전이 예방을 위한 약제, 동맥색전술용 국소 주입제 및 인공골
AU2015362790A1 (en) 2014-12-16 2017-07-20 Axovant Sciences Gmbh Geminal substituted quinuclidine amide compounds as agonists of alpha-7 nicotinic acetylcholine receptors
CN104610157A (zh) * 2015-02-13 2015-05-13 佛山市赛维斯医药科技有限公司 一类环丙基酰肼和卤代苯类结构的gpr119激动剂及其用途
RU2017145964A (ru) 2015-06-10 2019-07-10 Аксовант Сайенсиз Гмбх Аминобензизоксазольные соединения в качестве агонистов α7-никотиновых ацетилхолиновых рецепторов
WO2017027600A1 (en) 2015-08-12 2017-02-16 Forum Pharmaceuticals, Inc. GEMINAL SUBSTITUTED AMINOBENZISOXAZOLE COMPOUNDS AS AGONISTS OF α7-NICOTINIC ACETYLCHOLINE RECEPTORS

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5217983A (en) 1992-03-27 1993-06-08 Du Pont Merck Pharmaceutical Company (N-benzyl) acetaldehyde bicyclic heterocycles useful as topical antiinflammatories
JP2000511883A (ja) * 1996-04-19 2000-09-12 ノボ ノルディスク アクティーゼルスカブ ホスホチロシン認識ユニットを有する分子のモジュレーター
CN1246868A (zh) 1996-12-17 2000-03-08 扇形支撑剑桥有限公司 黑皮素
EA200700262A1 (ru) 2004-07-14 2007-08-31 Янссен Фармацевтика Н.В. Арилидены для лечения заболеваний, опосредуемых эстроген-родственным рецепторам альфа
JP5244118B2 (ja) * 2006-11-10 2013-07-24 ブリストル−マイヤーズ スクイブ カンパニー 新規キナーゼ阻害剤
EP2132188B1 (en) 2007-03-07 2011-12-14 Janssen Pharmaceutica N.V. Substituted phenoxy n-alkylated thiazoledinedione as estrogen related receptor-alpha modulators
CA2720215C (en) * 2008-04-16 2018-02-27 Karo Bio Ab Estrogen receptor ligands

Also Published As

Publication number Publication date
EP2536717B1 (en) 2014-06-04
AR080207A1 (es) 2012-03-21
TW201144303A (en) 2011-12-16
MX2012009529A (es) 2013-01-14
WO2011103134A1 (en) 2011-08-25
AU2011218190A1 (en) 2012-09-06
CN102834392A (zh) 2012-12-19
CA2789757A1 (en) 2011-08-25
EP2536717A1 (en) 2012-12-26
KR20130001242A (ko) 2013-01-03
US8445690B2 (en) 2013-05-21
RU2012139463A (ru) 2014-03-27
JP2013519730A (ja) 2013-05-30
US20110200587A1 (en) 2011-08-18

Similar Documents

Publication Publication Date Title
UY33231A (es) Aminotiazolonas como moduladores de los receptores de estrógenos alfa
PH12015502839A1 (en) Antiviral compounds
PH12014502141A1 (en) New indanyloxydihydrobenzofuranylacetic acid derivatives and their use as gpr40 receptor agonists
PE20151141A1 (es) Derivados triciclicos fusionados de tiofeno como inhibidores de jak
CO7141403A2 (es) Procesos para producir ciertos 2 (piridin 3 il)tiazoles
CO7141404A2 (es) Procesos para producir ciertos 2 (piridin 3 il)tiazoles
CR20140071A (es) Nuevos compuestos de 4-piperidinilo para uso como inhibidores de la tankirasa
ECSP11011517A (es) Compuestos antivirales
CR20140305A (es) Novedosas dihidropirimidinoisoquinolinonas y composiciones farmacéuticas de las mismas para el tratamiento de transtornos inflamatorios
UY33735A (es) Compuestos antivirales
PH12015501116A1 (en) New indanyloxydihydrobenzofuranylacetic acids
CU20140055A7 (es) Procedimiento de preparación de 5- fluoro- 1h-pirazolopiridinas sustituidas
UY35908A (es) Moduladores de tetrahidropiridopirazinas de gpr6
ECSP088693A (es) Inhibidores de quinasa basados en la hidantoina
ECSP10010475A (es) Derivados de azetidina y ciclobutano como inhibidores de jak
CO6541598A2 (es) Métodos de síntesis y purificación de compuestos de heteroarilo
IN2014MN02459A (es)
CO6721019A2 (es) Quinazolincarboxamida azetidinas
CO6771439A2 (es) Inhibidores de benzodioxano de la producción de leucotrieno
CO6480975A2 (es) Mimetico de smac
BR112012021865A2 (pt) derivados de ceto benzofurano, assim com o respectivo processo de síntese e os intermediários.
UY33118A (es) Indazoles aminotiazolona sustituidos como moduladores del receptor a relacionado con estrógenos
MX2016007128A (es) Compuestos del receptor 6 de quimiocina (ccr6).
BR112014014939A2 (pt) composição de tratamento de sementes
ECSP11010867A (es) Compuestos novedosos de fenilamino-isonicotinamida